Point of Care Diagnostics Market Size, Share, Trends, Industry Analysis, and Forecast (2025 – 2031)

Point of Care Diagnostics Market Size

The global point of care diagnosticsmarket size was valued at $17.19 billion in 2025 and is projected to reach $30.13 billion by 2031, growing at a CAGR of 9.8% during the forecast period.

Point of Care Diagnostics Market Overview

Point-of-care diagnostics, also known as point-of-care testing (POCT), involves conducting medical tests near the patient, rather than in a centralized laboratory. This approach enables faster results, allowing for quicker clinical decisions and improved patient outcomes by enabling early treatment. POCT encompasses a wide range of tests, including blood glucose monitoring, pregnancy tests, and rapid tests for infectious diseases like COVID-19.

Companies can benefit from POCT by developing innovative, cost-effective, and user-friendly devices that address unmet clinical needs. The integration of POCT into established clinical practice and the emerging trend towards smart devices equipped with mobile healthcare (mH) present significant opportunities for companies to revolutionize personalized healthcare monitoring and management, leading to improved patient outcomes and market growth.

Point of Care Diagnostics Market Dynamics

The point of care diagnosticsmarket is expected to witness significant growth in the future due to the increasing prevalence of chronic diseases, growing popularity of wearable or portable glucose monitoring devices, rising preference for homecare testing. However, the high costs associated with product development and testing kits, limited accuracy of point-of-care test, and unavailability of relevant and appropriate testing kits in certain regions are restraining the growth of the market.

Furthermore, strategic initiatives and collaborations among market players, Rising awareness and government funding for point-of-care diagnostics, and continuous technological advancements, including AI and IoT integration in testing devices are the key trends propelling the point of care diagnosticsmarket.

Increasing Prevalence of Chronic Diseasesis Driving the Point of Care Diagnostics Market

The increasing prevalence of chronic diseases is significantly impacting the point of care diagnosticsmarket, by driving demand for rapid testing solutions that facilitate timely diagnosis and management of these conditions.

• For instance, the global diabetic population is projected to reach 643 million by 2030 and 783 million by 2045, necessitating effective monitoring tools like glucose meters and related products.

Additionally, government initiatives are also contributing to this trend.

• For example, the U.S. government has supported the expansion of point-of-care testing through funding and policy changes aimed at enhancing healthcare accessibility, particularly in underserved areas.
• In 2022, the FDA approved several new diagnostic panels by bioMérieux and BD, which focus on infectious diseases that often accompany chronic conditions, such as HIV and tuberculosis. This regulatory support underscores the importance of rapid diagnostics in managing the growing burden of chronic diseases.

By Product, the Infectious Disease Testing ProductsSegment is projected to be the Largest Segment in the Point of Care Diagnostics Market

Infectious disease testing products is the largest segment in the point of care diagnosticsmarket, driven by increasing prevalence of infectious diseases globally and the need for rapid, accurate testing solutions.

Companies are actively launching innovative products to cater to this demand.

• For instance, in 2022, bioMérieux and BD received FDA approval for new diagnostic panels focusing on infectious diseases like HIV and tuberculosis.
• Additionally, in May 2022, miDiagnostics, a Belgium-based POC diagnostics company, launched a CE-IVD certified ultra-fast COVID-19 PCR test for decentralized testing.

Government initiatives are also supporting the expansion of infectious disease testing.

• In 2022, Unitaid invested $30 million to enhance diagnostic technologies, particularly in lower-tier healthcare systems in the Asia Pacific region.

Furthermore, the U.S. government has provided funding and implemented policy changes to improve healthcare accessibility and promote point-of-care testing for infectious diseases.The increasing prevalence of infectious diseases is driving the demand for rapid testing solutions.

• According to the WHO, around 38.4 million people were living with HIV in 2021, with 650,000 deaths related to HIV and 1.5 million new infections.Additionally, the WHO estimates that approximately 354 million people live with hepatitis B or C worldwide.

These alarming statistics underscore the urgent need for efficient point-of-care diagnostics to manage infectious diseases effectively.

By Geography, Asia PacificHolds the Largest Share in the Market Revenue

Asia Pacific holds the largest share of the point of care diagnosticsmarket, driven by the rising prevalence of chronic diseases, increasing healthcare expenditure, and a growing geriatric population.

• In 2022China, which accounted for over 40% of the market share, the aging population and the high incidence of chronic ailments such as cardiovascular diseases and diabetes are significant contributors to this demand.
• Companies like Abbott and F. Hoffmann-La Roche Ltd. are launching innovative portable diagnostic devices tailored for home healthcare, addressing the increasing preference for at-home testing solutions.
• For instance, in 2022, Abbott introduced the FreeStyle Libre 3, a continuous glucose monitoring system that allows patients to monitor their glucose levels conveniently at home.
• Additionally in September 2022, government initiatives, such as Unitaid's investment of USD 30 million to enhance diagnostic technologies, further support the expansion of point-of-care diagnostics across the region, particularly in lower-tier healthcare systems.

Key Target Audience:

• Point-of-care Diagnostic Product Manufacturers
• Distributors
• Clinical Laboratories
• Contract manufacturing organizations (CMOs)
• Contract research organizations (CROs)

List of the Key Players Profiled in the Report Includes:

• F. Hoffmann-La Roche Ltd.
• Qiagen
• Danaher Corporation
• Becton Dickinson (BD)
• bioMérieux
• Abbott
• Siemens Healthcare GmbH
• Werfen
• Nova Biomedical
• Trividia Health, Inc.
• QuidelOrtho Corporation
• Trinity Biotech

Recent Developments:

• In August 2024, Qiagen launched the QIAstat-Dx Respiratory SARS-CoV-2 Panel, which provides rapid testing for COVID-19 and other respiratory viruses.
• In June 2024, Danaher announced the achievement of Cepheid, a leader in molecular diagnostics, to enhance its point-of-care testing capabilities. This acquisition is expected to accelerate the development of rapid infectious disease tests, further solidifying Danaher's position in the diagnostics market.
• In February 2024, Siemens Healthineers introduced the Atellica VTLi Patient-Side Testing System, which enables rapid testing for various infectious diseases at the point of care.
• In January 2024, Werfen launched the AccuTnI+ cardiac troponin test, which allows for rapid assessment of heart attacks at the point of care. This product is part of Werfen's strategy to expand its diagnostics offerings in critical care settings.

Market Segmentation:

The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Product:

• Cardiometabolic Monitoring Products
• Cholesterol Testing Products
• Coagulation Monitoring Products
• COVID-19 Test Products
• Drugs-of-abuse Testing Products
• Fecal Occult Testing Products
• Glucose Monitoring Products
• Hematology Testing Products
• Infectious Disease Testing Products
• Pregnancy & Fertility Testing Products
• Thyroid Stimulating Hormone (TSH) Testing Products
• Tumor/Cancer Marker Testing Products
• Urinalysis Testing Products
• Other POC Products

Market by, Platform:

• Dipsticks
• Immunoassays
• Lateral Flow Assays
• Microfluidics
• Molecular Diagnostic

Market by, Mode of Purchase:

• Prescription-based Products
• OTC Products

Market by, Sample:

• Blood Sample
• Nasal and Oropharyngeal Swabs Sample
• Urine Sample
• Other Samples

Market by, End User:

• Ambulatory Care Facilities and Physician Offices
• Clinical Laboratories
• Home Care & Self Testing
• Hospitals, Critical Care Centers, Urgent care centers
• Pharmacies, retail clinics, & E-comm. Platforms
• Other End Users

Market by, Geography:

The point of care diagnosticsmarket report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:

• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis
• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis
• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis
• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

The report offers insights into the following aspects:

• Analysis of major market trends, factors driving, restraining, threatening, and providing opportunities for the market.
• Analysis of the market structure by identifying various segments and sub-segments of the market.
• Understand the revenue forecast of the market for North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
• Analysis of opportunities by identification of high-growth segments/revenue pockets in the market.
• Understand major player profiles in the market and analyze their business strategies.
• Understand competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product launches in the market.